Karyopharm Therapeutics Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 228

Employees

  • Stock Symbol
  • KPTIQ

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.03
  • (As of Thursday Closing)

Karyopharm Therapeutics General Information

Description

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 85 Wells Avenue
  • Suite 210
  • Newton, MA 02459-3298
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 85 Wells Avenue
  • Suite 210
  • Newton, MA 02459-3298
  • United States
+1 (617)

Karyopharm Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Karyopharm Therapeutics Stock Performance

As of 19-Nov-2026, Karyopharm Therapeutics’s stock price is $0.03. Its current market cap is $769K with 22.7M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.03 $0.04 $769K 22.7M 8.67M -$13.04

Karyopharm Therapeutics Financials Summary

As of 30-Jun-2026, Karyopharm Therapeutics has a trailing 12-month revenue of $147M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 361,441 276,040 146,077 68,322
Revenue 146,621 146,067 145,237 146,033
EBITDA (177,692) (152,624) (46,003) (129,366)
Net Income (224,740) (196,039) (76,422) (143,099)
Total Assets 111,317 108,416 164,418 240,438
Total Debt 256,192 233,607 194,524 177,016
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Karyopharm Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Karyopharm Therapeutics‘s full profile, request access.

Request a free trial

Karyopharm Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Karyopharm Therapeutics‘s full profile, request access.

Request a free trial

Karyopharm Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated
Drug Discovery
Newton, MA
228 As of 2026

Tokyo, Japan
 

Doylestown, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Karyopharm Therapeutics Competitors (60)

One of Karyopharm Therapeutics’s 60 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Astellas Pharma Corporation Tokyo, Japan
Aprea Therapeutics Formerly VC-backed Doylestown, PA
SpringWorks Therapeutics Formerly VC-backed Stamford, CT
Rigel Pharmaceuticals Formerly VC-backed South San Francisco, CA
Evotec Formerly PE-Backed Hamburg, Germany
You’re viewing 5 of 60 competitors. Get the full list »

Karyopharm Therapeutics Patents

Karyopharm Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024168062-A1 Selinexor and analogs for use in the treament of endometrial cancer in patients with wild-type tp53 gene Inactive 07-Feb-2023
WO-2024102477-A1 Crystalline forms of eltanexor and process for preparing same Inactive 11-Nov-2022
AU-2022276509-A1 Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms Pending 20-May-2021
CA-3219525-A1 Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms Pending 20-May-2021
EP-4341253-A1 Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms Pending 20-May-2021 C07D403/06
To view Karyopharm Therapeutics’s complete patent history, request access »

Karyopharm Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Karyopharm Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Karyopharm Therapeutics‘s full profile, request access.

Request a free trial

Karyopharm Therapeutics Investments (1)

Karyopharm Therapeutics’s most recent deal was a Corporate Asset Purchase with Neumedicines (HemaMax, an Investigational Interleukin 12 (IL-12) and Certain Assets) for . The deal was made on 22-Jul-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Neumedicines (HemaMax, an Investigational Interleukin 12 (IL-12) and Certain Assets) 22-Jul-2021 Corporate Asset Purchase Buildings and Property
To view Karyopharm Therapeutics’s complete investments history, request access »

Karyopharm Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

33.68 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Karyopharm Therapeutics’s complete esg history, request access »

Karyopharm Therapeutics FAQs

  • When was Karyopharm Therapeutics founded?

    Karyopharm Therapeutics was founded in 2008.

  • Where is Karyopharm Therapeutics headquartered?

    Karyopharm Therapeutics is headquartered in Newton, MA.

  • What is the size of Karyopharm Therapeutics?

    Karyopharm Therapeutics has 228 total employees.

  • What industry is Karyopharm Therapeutics in?

    Karyopharm Therapeutics’s primary industry is Drug Discovery.

  • Is Karyopharm Therapeutics a private or public company?

    Karyopharm Therapeutics is a Public company.

  • What is Karyopharm Therapeutics’s stock symbol?

    The ticker symbol for Karyopharm Therapeutics is KPTIQ.

  • What is the current stock price of Karyopharm Therapeutics?

    As of 19-Nov-2026 the stock price of Karyopharm Therapeutics is $0.03.

  • What is the current market cap of Karyopharm Therapeutics?

    The current market capitalization of Karyopharm Therapeutics is $769K.

  • What is Karyopharm Therapeutics’s current revenue?

    The trailing twelve month revenue for Karyopharm Therapeutics is $147M.

  • Who are Karyopharm Therapeutics’s competitors?

    Astellas Pharma, Aprea Therapeutics, SpringWorks Therapeutics, Rigel Pharmaceuticals, and Evotec are some of the 60 competitors of Karyopharm Therapeutics.

  • What is Karyopharm Therapeutics’s annual earnings per share (EPS)?

    Karyopharm Therapeutics’s EPS for 12 months was -$13.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process